MAPT and Alzheimer disease: According to the current diagnostic criteria of the National Institute on Aging and the Alzheimer’s Association (NIA-AA) [2], the diagnosis of AD includes specific neuropathological markers, namely amyloid-β (A +) and (phosphorylated) tau (T +), which can be detected in the CSF or in the brain by positron emission tomography (PET) [13].